Parkinson's disease is a progressive neurodegenerative movement disorder characterized by bradykinesia, rigidity, tremor, and non-motor symptoms due to dopaminergic neuronal loss.
Studies found gut microbiome changes linked to Parkinson’s risk before symptoms and hair mineral differences in diagnosed patients. Both findings need larger follow-up studies.
Two studies identify protein recycling dysfunction and transcription factors ZSCAN20/JDP2 as drivers of T-cell exhaustion, with E3 ligases and gene deactivation offering reversal pathways. A third study finds TCF1 insufficient to revert terminally exhausted T cells.
AbbVie filed an sBLA for SKYRIZI as a subcutaneous induction therapy for Crohn's disease, supported by Phase 3 AFFIRM data. SKYRIZI and Rinvoq combined for $25.9B in 2025 revenue, exceeding 2027 guidance. The FDA also approved Venclexta plus acalabrutinib in CLL.
AbbVie reported positive Phase 3 data for Skyrizi's subcutaneous Crohn's disease treatment and is advancing lutikizumab and Rinvoq in hidradenitis suppurativa, with multiple readouts expected throughout 2026 as the company pursues combination therapy strategies.
New market research reports analyze biotechnology collaboration agreements from 2020-2026, gas chromatography market growth projections, and Western blotting market trends through 2035.
New research reveals GLP-1 receptor agonists reduce substance use disorders by 14%, lower Parkinson's disease risk after 5-10 years of use, and cut endometrial cancer risk by 66% when combined with progestin therapy.
AI systems are evolving into essential research collaborators in 2026, while quantum computing emerges as a transformative technology with potential to create $200-500 billion in value for life sciences by 2035.
Prothena reported Q4 2025 adjusted loss of 45 cents per share, meeting estimates, while ending the year with $308.4 million in cash. Roche and Novo Nordisk advanced partnered programs prasinezumab and coramitug into Phase III trials.
Researchers demonstrate that a fully implanted brain device can detect walking states in Parkinson's patients during unsupervised daily activities, opening the door to adaptive deep brain stimulation therapies that adjust to real-world movement.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT06036433 |
Light Therapy Plus Exercise to Improve Motor, Non-Motor Symptoms and QoL in Parkinson's Disease |
UNKNOWN | NA |
| NCT05518617 |
Molecular and Functional Imaging in Monogenic PD. |
RECRUITING | |
| NCT05516732 |
Serotonin Release in Premotor and Motor PD |
RECRUITING | |
| NCT05516719 |
Longitudinal Investigation of I2BS in PD |
RECRUITING | |
| NCT02670161 |
Quality Improvement and Practice Based Research in Neurology Using the EMR |
ENROLLING_BY_INVITATION | PHASE4 |
| NCT02561715 |
Lack of Awareness of Symptoms (Anosognosia) in PD: An Observational Study for People With Parkinson's |
WITHDRAWN | |
| NCT02468804 |
Cognitive Dysfunction In Parkinson's |
COMPLETED | NA |
| NCT02315781 |
tDCS in Parkinson's Disease With Depression |
TERMINATED | NA |
| NCT02271685 |
Sound Estimation and Accuracy Task |
COMPLETED | NA |
| NCT02177149 |
Nurse Management of Neuromodulation Therapy |
WITHDRAWN | NA |
